Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome

Dong Hyun Kim; Junshik Hong; Dong-Yeop Shin; Inho Kim; Sung-Soo Yoon; Soo Mee Bang; Jeong-Ok Lee; Ji Yun Lee; Sang-A Kim; Ja Min Byun; Youngil Koh

doi:10.1111/bjh.19500

Phase II trial of posaconazole prophylaxis during anti-thymocyte globulin treatment for aplastic anaemia and hypoplastic myelodysplastic syndrome

Br J Haematol. 2024 Jul;205(1):356-359. doi: 10.1111/bjh.19500. Epub 2024 May 3.

Authors

Dong Hyun Kim¹, Junshik Hong^{1

2

3

4}, Dong-Yeop Shin^{1

2

3

4}, Inho Kim^{1

2}, Sung-Soo Yoon^{1

2

3

4}, Soo Mee Bang⁵, Jeong-Ok Lee⁵, Ji Yun Lee⁵, Sang-A Kim⁵, Ja Min Byun^{1

3}, Youngil Koh^{1

2

3

4}

Affiliations

¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
² Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
³ Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
⁴ Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea.
⁵ Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul, Korea.

PMID: 38699798
DOI: 10.1111/bjh.19500

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Adult
Aged
Anemia, Aplastic* / drug therapy
Antifungal Agents / therapeutic use
Antilymphocyte Serum* / therapeutic use
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes / complications
Myelodysplastic Syndromes / drug therapy
Triazoles* / therapeutic use

Substances

Antilymphocyte Serum
posaconazole
Triazoles
Antifungal Agents